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Abstract
Background: The effects of exercise training on Chagas heart disease are still unclear. This study aimed to evaluate
the effect of exercise training over functional capacity, cardiac function, quality of life, and biomarkers in Chagas
heart disease.
Methods: The PEACH study is a superiority randomized clinical trial which will include subjects who meet the
following criteria: Chagas heart disease with a left ventricular ejection fraction below 45 % with or without heart
failure symptoms; clinical stability in the last 3 months; adherence to clinical treatment; and age above 18 years.
The exclusion criteria are: pregnancy; neuromuscular limitations; smoking; evidence of non-chagasic heart disease;
systemic conditions that limit exercise practice or cardiopulmonary exercise test; unavailability to attend the center
three times a week during the intervention period; and practitioners of regular exercise. The intervention group will
perform an exercise training intervention three times per week during 6 months and will be compared to the
control group without exercise. Both groups will undergo the same monthly pharmaceutical and nutritional
counseling as well as standard medical treatment according to the Brazilian consensus on Chagas disease. The
primary outcome is functional capacity based on peak exercise oxygen consumption during cardiopulmonary
exercise testing. Secondary outcomes are: cardiac function; body composition; muscle respiratory strength;
microvascular reactivity; cardiac rhythm abnormalities; autonomic function; biochemical; oxidative stress and
inflammatory biomarkers; and quality of life. Subjects will be evaluated at baseline, and at 3 and 6 months after
randomization. Thirty patients will be randomly assigned into exercise or control groups at a ratio of 1:1.
Discussion: Findings of the present study will be useful to determine if physical exercise programs should be
included as an important additional therapy in the treatment of patients with Chagas heart disease.
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Background
Chagas heart disease (CHD) is the most common mani-
festation of chronic Chagas disease with prevalence of
20 to 30 % in patients infected with Trypanosoma cruzi
[1]. Patients with CHD present a high incidence of car-
diac complications, morbidity, and mortality in Latin
America [2]. The Brazilian consensus on Chagas disease
[3] classifies CHD into different stages that reflect prog-
nosis: stage A (abnormalities on electrocardiogram at-
tributable to Chagas disease and no left ventricular (LV)
wall motion abnormalities detected by echocardiog-
raphy), stage B1 (LV wall motion abnormalities with an
ejection fraction (EF) >45 % and no heart failure (HF)),
stage B2 (LVEF <45 % and no HF), stage C (compen-
sated HF), and stage D (endstage HF).
Currently, CHD therapy is based on treating symp-
toms and slowing the heart disease progression following
the standard guidelines for cardiac disease of other
etiologies [4]. However, some particular features in the
clinical course of CHD demand specific treatment.
Therefore, studies evaluating the effects of different
strategies on patients with CHD are necessary.
Treatment of heart disease requires a multidisciplinary
team-based care approach that includes exercise training
to improve patients’ functional status [5]. Cardiac rehabili-
tation (CR) is associated with consistent improvements in
symptoms, cardiac mortality, number of hospitalizations,
quality of life, and in numerous relevant clinical endpoints
[6]. Moreover, exercise programs have gained increased
recognition during the past years and have been strongly
recommended by many different cardiology societies in
the world, mainly for non-CHD [7–9].
However, exercise studies including patients with
Chagas disease are warranted since these patients are
usually not included in exercise clinical trials [10]. The
first study that addressed the effects of exercise training
on CHD showed that functional capacity, clinical symp-
toms, and some domains of health-related quality of life
(vitality, emotional aspects, and mental health) improved
after 3 months of follow-up [11]. Another single-arm
study demonstrated that oxygen consumption at peak of
exercise (VO2 peak), oxygen pulse (O2 pulse), and oxy-
gen consumption at anaerobic threshold (VO2 AT) im-
proved after 6 months of exercise training [12].
However, the interpretation of these results is limited by
the short-term follow-up in the former study and the
lack of a control group in the later study. Thus, new
well-designed clinical trials are necessary to improve the
knowledge of CR effects on patients with CHD.
The PEACH study, which stands for “Exercise Pro-
gram in Chagas Heart Disease” in Portuguese, is de-
signed to address the effects of exercise training in
patients with CHD. The primary aim of the study is to
investigate the effects of exercise on functional capacity
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in patients with CHD, measured as the VO2 peak during
a maximal progressive cardiopulmonary exercise test
(CPET). Secondary objectives are to assess the effects of
exercise training on cardiac function, body composition,
muscle respiratory strength, microvascular reactivity,
cardiac rhythm abnormalities, autonomic function, bio-
chemical, inflammatory and oxidative stress biomarkers,
and quality of life. We hypothesized that exercise train-
ing will be safe and will promote important clinical ben-




The PEACH study is a single-center, superiority random-
ized clinical trial (ClinicalTrials.gov ID: NCT02517632)
performed at the Evandro Chagas National Institute of In-
fectious Diseases (INI), a national reference center for
treatment and research in infectious and tropical diseases
in Rio de Janeiro, Brazil. The unit staff is composed of
infectious disease specialists, cardiologists, gastroenterolo-
gists, nurses, pharmacists, and exercise physiologists. Re-
sources such as echocardiography, computed tomography,
digestive endoscopy, 24-h Holter electrocardiogram moni-
toring, ambulatory blood pressure monitoring, CPET, and
cardiac rehabilitation are also available. The institute has
outpatient and inpatient treatment sectors with an inten-
sive care unit.
Participants and recruitment
Individuals followed at INI will be sequentially recruited
to participate in the study. The eligibility criteria are: (1)
Chagas disease diagnosis, confirmed by two simultan-
eous serological tests (enzyme-linked immunosorbent
assay (ELISA) and indirect immunofluorescence) [3], (2)
CHD with LVEF <45 % with or without HF symptoms at
baseline evaluation (CHD stages B2 and C), (3) New
York Heart Association class I or II in the previous
3 months, with clinical stability by investigator judg-
ment, (4) clinical treatment according to HF guidelines,
including treatment with angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers, and beta-
blocker therapy, or documented rationale for variation,
including intolerance, contraindication, or patient pref-
erence [13, 14]. Patients will be on stable doses of medi-
cations for 6 weeks prior to enrollment, and (5) age
above 18 years. Exclusion criteria are: (1) pregnancy, (2)
neuromuscular limitations that preclude physical exer-
cise, (3) smoking, (4) evidence of known non-chagasic
heart disease, (5) systemic conditions that limit exercise
practice or CPET, (6) unavailability to attend the center
three times a week during the intervention period, and
(7) practitioners of regular exercise.
Trained research assistants or study investigators will
conduct the evaluations in a quiet and private room. Ini-
tial interviews will include a questionnaire to collect socio-
demographic data (income, race, age, sex, and schooling),
medical history (stage of CHD, comorbidities, medication,
cardiac devices, and arrhythmias), functional class, and
level of physical activity through the International Physical
Activity Questionnaire-Short Form (IPAQ-SF). Evalua-
tions of functional capacity (maximal progressive CPET),
cardiac function (two-dimensional echocardiography),
body composition (anthropometry and skinfolds), muscle
respiratory strength (manovacuometry), microvascular
reactivity (laser speckle flowmetry), cardiac rhythm abnor-
malities (24-h Holter), autonomic function (active ortho-
static stress test), laboratorial biomarkers (biochemical,
inflammatory, and oxidative stress), and quality of life
(Short Form-36 (SF36) and Minnesota Living with Heart
Failure Questionnaire) will be performed at baseline, after
3 months, and at the end of follow-up (6 months). After
initial evaluation, patients will be randomized to interven-
tion or control groups as seen in Fig. 1.
Intervention
Patients included in the intervention arm will be submit-
ted to an exercise training performed three times a week
for 60 min, during a 6-month period. Each session will
comprise 30 min of aerobic exercise on a treadmill or
cycle ergometer (the first 5 min of warm-up and the last
5 min of cool-down), 20 min of strength exercises for
the major muscle groups (sit-ups, push-ups, and pull-
ups), and 10 min of stretching. The exercise intensity
will be set according to the heart rate obtained during
the CPET, corresponding to the anaerobic threshold
minus 10 % in the first month of exercise protocol and
the anaerobic threshold plus 10 % in the following
months. Blood pressure, heart rate, and oxygen satur-
ation will be measured before, during aerobic exercise
(at 20 min of aerobic exercise), and at the end of each
training session using an aneroid sphygmomanometer
(Unitec, São Paulo, Brazil), a heart rate monitor (Polar
FT1, Kempele, Finland), and an oximeter (IMFtec®, São
Paulo, Brazil). Individuals with long QT syndrome, atrial
fibrillation or flutter with ventricular response less than
100 bpm at rest, frequent premature ventricular contrac-
tions, sinus tachycardia, sinus bradycardia, or patients
with any cardiac related-symptoms will have their
rhythm observed with a cardiac monitor during the ex-
ercise sessions. Glucose monitoring will be performed
before and after exercise sessions in diabetic patients to
guarantee its safety. For pre-exercise blood glucose levels
of less than 100 mg.dL−1 (5.5 mmol.L−1), the American
Diabetes Association recommends that carbohydrate
should be ingested before any exercise. The patient will
be able to engage in exercise with levels exceeding
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300 mg.dL−1 (16.7 mmol.L−1) unless they present with
ketosis symptoms, or dehydration [15]. All training ses-
sions will be performed in the morning, indoors, and
with a controlled temperature environment under super-
vision of medical staff.
Patients of both groups will undergo regular med-
ical appointments with the same cardiologist during
the follow-up based on standard medical treatment of
the Brazilian consensus on Chagas disease recommen-
dations [3] and with other medical specialties if ne-
cessary. In addition, nutritional and pharmaceutical
counseling will be provided monthly for both groups.
The nutritional counseling will consist of general
guidance about healthy eating habits and will include
how to reduce saturated fat and include poly and
monounsaturated fatty acids, to consume more vita-
mins, high-fiber carbohydrates, and to reduce the so-
dium and water intake for patients with HF [16, 17].
Pharmacists will guide patients about medication
usage, drug dosage, and compliance. In order to re-
duce any bias due to medication noncompliance, all
patients will receive monthly personalized packages
according to the medical prescription. The pills will
be organized by the time and days that the pills
should be taken (Fig. 2). The schedule of enrollment,
interventions, and assessments of the PEACH study is
seen in Fig. 3 and the Standard Protocol Items: Rec-
ommendations for Interventional Trials (SPIRIT)
checklist in Additional file 1.
Outcomes
These will be functional capacity, cardiac function, body
composition, muscle respiratory strength, microvascular
reactivity, cardiac rhythm abnormalities, autonomic
function, biochemical, oxidative stress and inflammatory
biomarkers, and quality of life will be assessed at base-
line, 3 months, and 6 months of the study.
Cardiopulmonary exercise test
The primary outcome is functional-capacity-based on
VO2 peak obtained by a CPET using the VO2000 gas
analyzer (MedGraphics®, St. Paul, MS, USA) with a com-
puterized system Ergo PC Elite (Micromed®, Brasília,
Brazil) and a treadmill (Inbramed®, Porto Alegre, Brazil).
A blinded evaluator will perform an incremental exercise
test using a ramp protocol, tailored to achieve a fatigue
limited exercise duration of approximately 8 to 12 mi-
nutes. [18]. The workloads will be based on age, gender,




Patients recruitment: Chagas Heart 
disease stages B2 and C
Patients agree to 
participate?
Exclusion
Screening: cardiopulmonary exercise test,
echocardiogram, body composition, respiratory muscle 
strength test, microvascular reactivity evaluation, 24h-
Holter, cardiovascular autonomic function test, 










Outcome data collection: cardiopulmonary exercise test,
echocardiogram, body composition, respiratory muscle 
strength test, microvascular reactivity evaluation, 24h-
Holter, cardiovascular autonomic function test, 
laboratorial biomarkers and quality of life questionnaires.
Fig. 1 Flow diagram of the PEACH study protocol
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height, and weight; adapted to each subject’s physical
condition and effort tolerance. Gas and volume calibra-
tions will be executed on the early morning of each test
day. Pulmonary gas exchange will be analyzed breath-
by-breath and averaged every 10 s. A 12-lead electrocar-
diogram will monitor heart rhythm during CPET.
The CPET will be limited by symptoms through the
subjective fatigue perception scale (Borg modified) ran-
ging from 0 to 10, with 0 representing absence of fatigue
and 10 maximum tolerated efforts. The examiner may
interrupt the test in case of identification of any harmful
hemodynamic response. The recovery phase will be
active with walking in a pre-determined velocity of
2 km.h−1 and 2 % of inclination.
The following CPET variables will be analyzed: max-
imum achieved heart hate (HRmax); maximum achieved
blood pressure (BPmax); respiratory exchange ratio
(VCO2/VO2); oxygen consumption at peak of exercise
(VO2 peak); oxygen consumption at anaerobic threshold
(VO2 AT); oxygen pulse (O2 pulse); ventilation slope
equivalent to carbon dioxide production (slope VE/
VCO2); circulatory power (CP); presence of complex ven-
tricular arrhythmias (VA); functional aerobic impairment
(FAI); and oxygen uptake efficiency slope (OUES) values.
The VO2 peak during exercise will be defined as the
greatest value during 30 s before and after maximum
effort. The VO2 AT will be determined by the point at
which expired carbon dioxide increases in a nonlinear
fashion relative to the rate of oxygen consumption accord-
ing to the V-slope method. Ergo PC Elite software will de-
termine the other variables obtained on the CPET.
Before CPET, the rest electrocardiogram will be evalu-
ated to define if the cardiac rhythm is acceptable to per-
form the exam. The following markers will not be
accepted: sustained ventricular tachycardia, second- and
third-degree atrioventricular block, atrial or supraven-
tricular tachycardia (more than 100 bpm).
Cardiac function
Patients will undergo a standard two-dimensional resting
echocardiogram using a phased-array ultrasound system
(Vivid 7, General Electric Medical Systems®, Milwaukee,
WI, USA) equipped with a M4S transducer. Cardiac di-
mensions, LV and right ventricular (RV) systolic func-
tion, and Doppler measurements will be measured as
recommended by the American Society of Echocardiog-
raphy [19–21]. The biplane Simpson’s method will be
used to estimate LVEF. The other studied variables will
be as follows: RV peak systolic myocardial velocity
(RVS), tricuspid annular plane systolic excursion
(TAPSE), RV systolic pressure, peak early (E) and late
Fig. 2 Medication packages
Mendes et al. Trials  (2016) 17:433 Page 5 of 11
(A) diastolic filling velocities, E/A ratio, peak, and peak
early (E’) diastolic myocardial velocities.
Body composition
The anthropometric evaluation will consist of measure-
ments of body weight and height with minimal clothing
and without shoes using a calibrated digital scale with
coupled stadiometer. A ratio between weight (kg) and
squared height (m) will determine body mass index
(BMI), an important surrogate of nutritional status
[22]. Two circumferences will be taken: the waist cir-
cumference at the narrowest waist level and the hip
circumference at the largest circumference around the
buttocks [23].
A seven-site skinfold thickness protocol including
chest, midaxillary, triceps, subscapular, abdomen, suprai-
liac, and thigh sites will be used to evaluate body
composition. Measurements will be taken twice on the
right side of the body while standing in a relaxed
position (Lange skinfold caliper, Beta Technology Inc.,
Cambridge, MD, USA). The average of each of these
seven skinfold thickness will be summated and used to
estimate body composition using the Jackson and Pol-
lock equation [24, 25].
Respiratory muscle strength
Respiratory muscle strength will be assessed by maximal
inspiratory (MIP) and expiratory pressures (MEP) using
a digital pressure manometer connected to a mouthpiece
(MVD 3000®, Globalmed, Brazil). Patients will remain in
a seated position with a nose clip. They will be requested
to make a maximum inspiratory effort at residual vol-
ume and a maximum expiratory effort at total lung cap-
acity, sustaining it for 1 to 2 s [26]. Once the operator is
satisfied, the maximum value of three maneuvers that
vary by less than 20 % will be recorded [27].
Microvascular reactivity
A laser speckle contrast imaging system with a laser
wavelength of 785 nm (PeriCam PSI system, Perimed,
Järfälla, Sweden), coupled to iontophoresis of acetylcho-
line and sodium nitroprusside, will noninvasively meas-
ure real time cutaneous microvascular flow changes in
the forearm [28, 29].
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out
TIMEPOINT
January 















Nutritional and pharmaceutical 
counseling
X X X X X X
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biochemical, oxidative stress 
and inflammatory biomarkers, 
and quality of life]
X X X X
*m: month
Fig. 3 Schedule of enrollment, interventions, and assessments of the PEACH study
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For the post-occlusive reactive hyperemia (PORH) test,
arterial occlusion will be performed with suprasystolic
pressure (50 mmHg above the systolic arterial pressure)
using a sphygmomanometer applied to the arm of the
subject over 3 min. Peak skin flow will be measured after
pressure release.
Images will be analyzed using the manufacturer’s
software (PIMSoft, Perimed, Järfälla, Sweden). The
measurements of skin blood flow will be divided by
the mean arterial pressure to yield the cutaneous vas-
cular conductance (CVC) in arbitrary perfusion units
(APU)/mmHg, to avoid interference of blood pressure
levels on microvascular flow.
Cardiac rhythm abnormalities
Arrhythmias and heart rate variability (HRV) will be
evaluated with a 24-h Holter (portable three-channel re-
corder and analyzer; Cardio Light® and CardioSmart® 5.0,
Cardio System, São Paulo, Brazil). Patients will be re-
quested to maintain their normal daily activities during
the exam. Standard frequency- and time-domain heart
rate variability indexes will be measured and evaluated
in patients who do not have artificial pacing or atrial fib-
rillation rhythm. Only tracings of at least 18 h will be
studied. Standard time-domain HRV indices (SDNN:
standard deviation of normal-to-normal RR intervals;
SDANN: standard deviation of the averages of normal-
to-normal RR intervals in all 5-min segments of a 24-h
recording; SDNNIDX: mean of the standard deviations
of normal-to-normal RR intervals in all 5-min segments
of a 24-h recording; rMSSD: root mean square of
successive differences; and PNN >50: percentage of
differences between adjacent normal-to-normal RR in-
tervals that are greater than 50 ms) and frequency do-
main (TP: total power; VLFP: very low-frequency power;
LFP: low-frequency power; HFP: high-frequency power)
will be calculated [30–32].
Cardiovascular autonomic function test
The active orthostatic stress test consists of the evalu-
ation of the heart rate and blood pressure response ob-
tained from orthostatic change. The patient will rest for
5 min in the supine position, which will be followed by a
quick stand-up position (3 to 5 s). The electrocardio-
gram will be digitally recorded (ErgoMet 13 V1.0.3.0
HW Heart Ware, Porto Alegre, Brazil) 10 s before the
maneuver and will last until 40 s after. The RR intervals
will be measured throughout the test period. The
baseline average heart rate will be based on the 10 RR
intervals immediately preceding the maneuver. The
maximum RR at rest over the minimum RR after
standup ratio will be calculated (index max:min RR)
[33]. The blood pressure will be measured after 5 min at
rest and the systolic blood pressure at 5 s after standing
with diastolic blood pressure collected within 5 s after
recording systolic blood pressure immediately after
standing up to evaluate postural hypotension. Patients
with artificial pacing or atrial fibrillation rhythm during
the exam will not be evaluated.
Laboratorial biomarkers
A laboratory accredited by the College of American
Pathologists will perform biochemical measurements.
Total cholesterol, high-density lipoprotein (HDL) chol-
esterol, triacylglycerol, glucose, glycated hemoglobin,
and the N-terminal of the prohormone brain natriuretic
peptide (NT-proBNP) will be measured using Siemens
Dimension® reagent cartridge with an intra- and inter-as-
say coefficient of variation (CV) <5 %. The Friedewald
equation, based on the triacylglycerol measures, will be
used to determine low-density lipoprotein (LDL) choles-
terol and very low-density lipoprotein (VLDL) choles-
terol concentrations [34].
Cytokine serum levels will be measured accordingly to
the manufacturer’s instructions (EBioscience, San Diego,
CA, USA). Antibodies specific for interferon gamma
(IFN-γ), tumor necrosis factor (TNF), interleukin-beta 1
(IL-1β), interleukin-10 (IL-10), interleukin-4 (IL-4),
interleukin-8 (IL-8), or monocyte chemotactic protein 1
(MCP-1) will be coated onto the 96-well ELISA micro-
plate overnight. Washing solution will be added to each
well three times. Standards and unknown samples will
be pipetted into these wells and will be incubated for
2 h. After washing, a biotinylated (detection) antibody
specific for the described cytokines will be added and in-
cubated for 1 h. After washing, streptavidin-horseradish
peroxidase will be added. After incubation for 30 min
and washing to remove all unbound enzyme, color de-
velopment solution will be added. Then, the plates will
be read using a microplate reader (SpectraMax 190,
Molecular Devices, Sunnyvale, CA, USA) at 450 nm.
Oxidative stress will be accessed by two different meth-
odologies: detection of serum carbonylated proteins and
reduced/oxidized glutathione ratio. The oxidative modi-
fied serum proteins will be detected after derivatization
with 2,4-dinitrophenylhydrazine, through generation of
dinitrophenylhydrazone, which will be analyzed in a
spectrophotometer at 380 nm [35]. The reduced and ox-
idized glutathione pool will be determined in patients’
sera using DetectX® Glutathione Fluorescent Detection
Kit (Arbor Assays, Ann Arbor, MI, USA) as recom-
mended by the manufacturer.
Quality of life
The short-form version of the SF-36 Health Survey [36]
and the Minnesota Living with Heart Failure Question-
naire [37] will be used to assess quality of life, all of
them previously translated and validated in Portuguese.
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The SF-36 consists of 36 questions in eight different
domains: general health, physical functioning, social
functioning, mental health, physical role, emotional role,
bodily pain, and vitality. Each of these dimensions range
from 0 (worst possible health state) to 100 (best possible
health state).
The Minnesota Living with Heart Failure Questionnaire
has 21 questions about how the heart disease influences
the lifestyle related to physical, psychological, and social
areas. Each question’s responses range from 0 (none) to 5
(very much) and the maximum score is 105. In this ques-
tionnaire, lower scores mean better quality of life.
Sample size
Considering a difference in peak oxygen intake of
2.9 ml.kg−1.min−1 with a standard deviation of
2.0 ml.kg−1.min−1 [38], assuming an α = 0.05 and β = 0.20,
and increasing the sample size by 50 % accounting for
losses to follow-up, a total of 30 patients (15 in the control
group and 15 in the exercise group) will be included.
Randomization
A sequence will be computer-generated to randomly
allocate 30 patients into two groups in a 1:1 ratio
(WinPepi version 11). The sequence will be generated in
blocks and by strata of CHD classification (B2 and C) by
a single researcher not involved in recruitment. Opaque
envelopes will be filled in sequentially to either control
or exercise group. Block size will be blinded from inves-
tigators involved in patients’ recruitment.
Blinding
Given that exercise implies a behavioral intervention, it is
not feasible to blind the patients. However, the evaluators
will be blinded to the primary endpoint obtained by the
CPET and the following secondary endpoints: microvascu-
lar reactivity, cardiac rhythm abnormalities, cardiovascular
autonomic function test, and laboratorial biomarkers. A
blinded researcher will perform all data analysis.
Interim analysis and stopping rules
Three interim analyses are planned. The first will be
conducted when the tenth volunteer completes 3 months
of follow-up, the second when the twentieth volunteer
completes 3 months of follow-up and the third when the
last volunteer completes 3 months of follow-up.
Trial interruption for ethical reasons due to either posi-
tive or negative results exceeding expectations may be
recommended by an independent committee. The pre-
specified stopping rule is a difference of 50 % in VO2 peak
between groups, serious adverse events twice as frequent
in one of the groups as cardiovascular death, acute myo-
cardial infarction, unstable angina, cardiopulmonary ar-
rest, malignant ventricular arrhythmias, decompensated
HF, and stroke. All these estimates should have a signifi-
cance level of 0.01 or less in any of the interim analyses.
Statistical analysis
Descriptive analysis will consist of mean and standard
deviation for continuous variables and percentage for
categorical variables. Skewness and Kurtosis testing will
be performed to assess the normality of data which will
be log-transformed in case of skewed distribution. Vari-
ables that can change prognosis of the disease will be
compared at baseline in relation to the exercise and con-
trol groups. Longitudinal effects of exercise on primary
and secondary outcomes will be evaluated through linear
mixed models (LMM), which correlate with repeated
measures over the time. LMM is an intention-to-treat
analysis as it includes all observations of each one of the
patients regardless of losses to follow-up or noncompli-
ance to exercise protocol. The longitudinal analysis will
be made by the treatment × time interaction, which esti-
mates the rate of changes in the outcomes. Residual
plots of all models will be examined and the likelihood-
ratio test will be used to compare and select random
intercept or random slope models.
The REDCap software will be used for data man-
agement and the data analysis will be conducted by
Stata 13.0 software. Statistical significance will be set
at p < 0.05 for all analyses.
Discussion
Despite major advances in cardiovascular therapies,
CHD still stands as an important cause of premature
death in Latin America. Although the number of new
cases of Chagas disease has decreased steadily since the
late 1990s, many chronic cases are still part of routine
care in public hospitals where patients with lower in-
come have access to treatment. Moreover, decreased
barriers to international travel and migration has led to
an increase in migration of patients from Chagas
disease-affected areas to nonendemic countries of North
America and Europe. This globalization phenomenon
transformed Chagas disease into a global medical chal-
lenge [39, 40].
CHD treatment is based on trials that studied the
effect of different drugs on ventricular dysfunction,
survival, and quality of life in patients with cardiomyopa-
thies from other etiologies [4, 41]. However, CHD has a
specific autonomic imbalance, a different pattern of
myocardial fibrosis associated with an inflammatory
milieu generated by parasite and host defenses, an
increased risk of complex arrhythmias and a known
worse prognosis than cardiomyopathies from other
etiologies [42, 43].
Exercise training is becoming an important strategy in
the treatment of patients with cardiac diseases. Numerous
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studies demonstrate that regular exercise is safe and
associated with substantial benefits in patients with
cardiovascular disease, mainly from ischemic etiology.
Clinical adaptations to exercise training include improve-
ments in functional capacity, enhancements in cardiac and
vascular function, autonomic nervous system modulation,
decreases in oxidative stress and low-grade inflammation,
and improvements in lipid and glucose profiles [44, 45].
Despite these well-established benefits of exercise
training in cardiac patients, there are few studies analyz-
ing its effects on patients with CHD. Currently, only one
randomized clinical trial [11] including 40 patients with
CHD showed that exercise induced improvements in
functional capacity and health-related quality of life. This
study demonstrates that exercise is feasible, effective,
and safe in patients with CHD but with restrictions as
the indirect measurement of VO2 peak, the short-term
follow-up and the inclusion of patients in the early
stages of CHD, which preclude a definite conclusion
about the effects of exercise training in this population.
In the PEACH study, we will try to fill this knowledge
gap and address the issue of whether patients with CHD
have the same benefits promoted by exercise training in
patients with cardiomyopathies from other etiologies. We
hypothesize that exercise training will be safe and promote
improvements in functional capacity and quality of life, as
previously demonstrated by Lima et al. [11] and Fialho et
al. [12] in a different sample of patients with CHD. Since
an exacerbated inflammatory response is an important
mechanism involved in the development of CHD [46] and
because several studies have been demonstrating an im-
portant anti-inflammatory property of exercise training
[47], a decrease in the serum levels of pro-inflammatory
cytokines and an increase in the serum levels of anti-in-
flammatory cytokines in patients with CHD in the exercise
group is expected. Although enhancements in autonomic
function as results of exercise training are present in stud-
ies with other cardiomyopathies [48], a recent article did
not confirm this finding in patients with CHD [30]. We
also hypothesize that cardiac function will improve by an
increase in LVEF and an improvement in diastolic func-
tion, as seen in coronary artery disease [49], and that exer-
cise will improve body composition, respiratory strength,
microvascular reactivity, and oxidative stress agents based
on results from studies evaluating exercise in non-CHD
patients [50, 51].
The benefits of exercise training that will be described
by this study will set a new treatment strategy for CHD
patients and that this strategy could be routinely in-
cluded in clinical practice.
Trial status
Participants are currently being recruited.
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